VALOR-HCM is designed to provide direct clinical evidence of mavacamten’s ability to mitigate the need for invasive SRT procedures and is the first of several potential studies planned by MyoKardia to expand on the existing body of evidence supporting mavacamten’s use as a potential backbone therapy for HCM. VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options, including those who have severe symptoms (NYHA Class IV). (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. (Nasdaq: MYOK), please note that the second quote by Jeffrey B.
03, 2020 (GLOBE NEWSWIRE) - In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc.
